Dimerix (ASX:DXB) has announced that the first patient has completed the ACTION3 Phase 3 clinical trial, including the initial follow-up period, and has chosen to enter the global open-label extension study.
Dimerix announces that first patient enters DMX-200 open label extension
September 10, 2024 Latest NewsLatest Video
New Stories
-
Immutep says its candidate in combination with Keytruda delivered positive efficacy and safety profile
September 16, 2024 - - Latest News -
Medicines Australia responds to questions on the HTA Review
September 16, 2024 - - Latest News -
The HTA Review report - 'Red Flag' number two of five
September 16, 2024 - - Latest News -
Australian company Kazia executes licensing agreement with QIMR Berghofer
September 16, 2024 - - Latest News -
A statement with intent that limits expectations and frames reform as a one-sided trade-off
September 16, 2024 - - Latest News -
The HTA Review report - 'Red Flag' number one of five
September 16, 2024 - - Latest News -
Pharmac announces plan to deploy more of its recent funding boost
September 16, 2024 - - Latest News